icad (ICAD) Stock Price, News & Analysis

Company Overview

iCAD, Inc. is a Nashua, New Hampshire–based medical technology company specializing in digital oncology solutions and treatment planning software. With a focus on early cancer detection and therapy workflow optimization, iCAD develops and markets advanced imaging and radiation treatment systems designed to improve clinical outcomes and streamline patient care. The company’s product suite leverages artificial intelligence, advanced algorithms and proprietary image-analysis tools to assist radiologists, oncologists and cancer centers in delivering personalized, efficient care.

Among iCAD’s flagship offerings is the ProFound AI® platform, an FDA-cleared deep-learning solution for mammography and digital breast tomosynthesis that enhances lesion detection and reduces reading times. In the therapeutic realm, iCAD markets the Xoft® Axxent® Electronic Brachytherapy System, an intraoperative radiation therapy (IORT) device that delivers targeted radiation at the time of surgery, minimizing exposure to healthy tissues. Complementing these core products, the company offers a suite of oncology workflow and data-management tools designed to integrate with existing health-system infrastructures.

Founded in 1984 as a digital design and imaging specialist, iCAD has evolved through strategic acquisitions and in-house innovation to become a recognized leader in AI-driven cancer detection technologies. The company maintains a direct sales presence in North America while partnering with distributors across Europe, Asia and other key markets to broaden its global footprint. iCAD’s research and development teams collaborate with leading academic institutions and clinical partners to validate and refine new applications for its imaging and treatment platforms.

Under the leadership of President and CEO Brent D. Shafer, iCAD continues to expand its product pipeline and pursue regulatory clearances worldwide. By combining advanced software, data analytics and targeted radiation solutions, the company aims to support healthcare providers in delivering earlier diagnoses, more precise treatments and improved patient outcomes in the fight against cancer.

Key Stats

• Today's Range: $3.68 to $3.80
• 50-Day Range: $3.42 to $3.99
• 52-Week Range: $1.19 to $4.02
• Volume: 141,449 shs
• Average Volume: 419,523 shs
• Market Capitalization: $102.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

icad Stock Analysis - MarketRank™

icad scored higher than 16% of companies evaluated by MarketBeat, and ranked 602nd out of 655 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for icad.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of icad is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of icad is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

icad has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.04% of the float of icad has been sold short.

Short Interest Ratio / Days to Cover

icad has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in icad has recently decreased by 9.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

icad does not currently pay a dividend.

Dividend Growth

icad does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.04% of the float of icad has been sold short.

Short Interest Ratio / Days to Cover

icad has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in icad has recently decreased by 9.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.39

News Sentiment

icad has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for icad this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for ICAD on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, icad insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.29% of the stock of icad is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.61% of the stock of icad is held by institutions.

ICAD Stock Analysis - Frequently Asked Questions

How have ICAD shares performed this year?

icad's stock was trading at $1.83 at the start of the year. Since then, ICAD shares have increased by 103.3% and is now trading at $3.72.

How were icad's earnings last quarter?

icad inc. (NASDAQ:ICAD) announced its quarterly earnings data on Tuesday, May, 13th. The technology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. The technology company had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.54 million. icad had a negative trailing twelve-month return on equity of 15.03% and a negative net margin of 26.63%.

How do I buy shares of icad?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of icad own?

Based on aggregate information from My MarketBeat watchlists, some other companies that icad investors own include Enovix (ENVX), Globant (GLOB), Rambus (RMBS), Luminar Technologies (LAZR), Toast (TOST), COMPASS Pathways (CMPS) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: COMP - SOFTWARE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ICAD
• CIK: 749660
• Web: www.icadmed.com
• Phone: (603) 882-5200
• Fax: 603-880-3843
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.62 million
• Net Margins: -26.63%
• Pretax Margin: -26.28%
• Return on Equity: -15.03%
• Return on Assets: -11.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.66
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: $19.53 million
• Price / Sales: 5.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 3.44

Miscellaneous

• Outstanding Shares: 27,471,000
• Free Float: 24,644,000
• Market Cap: $101.92 million
• Optionable: Optionable
• Beta: 1.37